BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $IONS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05392114-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Donidalorsen readout (P3) · Ionis Pharmaceuticals\, Inc. $IONS
DESCRIPTION:A Study to Assess the Long-Term Safety and Efficacy of Donidalo
 rsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)\n\nPrima
 ry completion date: 2026-12 (estimated) — month only\, shown on the 1st\
 nOriginally planned: 2024-10 (+26.0 months)\nPhase 3 · Rare · Hereditary
  Angioedema\nEnrollment: 154 · Sites: 50\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05392114\n
 https://clinicaltrials.gov/study/NCT05392114
URL:https://datacutoff.com/radar.html?nct=NCT05392114
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681351-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Olezarsen readout (P3) · Ionis Pharmaceuticals\, Inc. $IONS
DESCRIPTION:CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcu
 taneously to Participants With Severe Hypertriglyceridemia (SHTG)\n\nPrima
 ry completion date: 2027-03 (estimated) — month only\, shown on the 1st\
 nOriginally planned: 2026-05 (+10.0 months)\nPhase 3 · Cardio-Met · Seve
 re Hypertriglyceridemia\nEnrollment: 885 · Sites: 262\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT05681351\nhttps://clinicaltrials.gov/study/NCT05681351
URL:https://datacutoff.com/radar.html?nct=NCT05681351
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05185843-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Olezarsen readout (P3) · Ionis Pharmaceuticals\, Inc. $IONS
DESCRIPTION:A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Admi
 nistered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously
  Treated With Volanesorsen\n\nPrimary completion date: 2027-06 (estimated)
  — month only\, shown on the 1st\nOriginally planned: 2024-12 (+30.0 mon
 ths)\nPhase 3 · Other · Familial Chylomicronemia Syndrome\nEnrollment: 2
 4 · Sites: 11\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://tria
 lsonar.netlify.app/radar.html?nct=NCT05185843\nhttps://clinicaltrials.gov/
 study/NCT05185843
URL:https://datacutoff.com/radar.html?nct=NCT05185843
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06914609-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~obudanersen readout (P3) · Ionis Pharmaceuticals\, Inc. $IONS
DESCRIPTION:REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syn
 drome\n\nPrimary completion date: 2027-08 (estimated) — month only\, sho
 wn on the 1st\nPhase 3 · Rare · Angelman Syndrome\nEnrollment: 156 · Si
 tes: 40\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://trialsonar.
 netlify.app/radar.html?nct=NCT06914609\nhttps://clinicaltrials.gov/study/N
 CT06914609
URL:https://datacutoff.com/radar.html?nct=NCT06914609
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604974-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~ION775 readout (P2) · Ionis Pharmaceuticals\, Inc. $IONS
DESCRIPTION:A Study to Assess the Safety\, Tolerability and Efficacy of ION
 775\n\nPrimary completion date: 2027-09 (estimated) — month only\, shown
  on the 1st\nPhase 2 · Cardio-Met · Hypertriglyceridemia\, Severe Hypert
 riglyceridemia\nEnrollment: 72 · Sites: 18\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07604974
 \nhttps://clinicaltrials.gov/study/NCT07604974
URL:https://datacutoff.com/radar.html?nct=NCT07604974
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
